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Abstract
Background: Infections sustained by multidrug-resistant (MDR) and pan-resistant Acinetobacter
baumannii have become a challenging problem in Intensive Care Units. Tigecycline provided new
hope for the treatment of MDR A. baumannii infections, but isolates showing reduced susceptibility
have emerged in many countries, further limiting the therapeutic options. Empirical combination
therapy has become a common practice to treat patients infected with MDR A. baumannii, in spite
of the limited microbiological and clinical evidence supporting its efficacy. Here, the in vitro
interaction of tigecycline with seven commonly used anti-Acinetobacter drugs has been assessed.
Methods: Twenty-two MDR A. baumannii isolates from Intensive Care Unit (ICU) patients and
two reference strains for the European clonal lineages I and II (including 3, 15 and 6 isolates that
were resistant, intermediate and susceptible to tigecycline, respectively) were tested. Antimicrobial
agents were: tigecycline, levofloxacin, piperacillin-tazobactam, amikacin, imipenem, rifampicin,
ampicillin-sulbactam, and colistin. MICs were determined by the broth microdilution method.
Antibiotic interactions were determined by chequerboard and time-kill assays. Only antibiotic
combinations showing synergism or antagonism in both chequerboard and time-kill assays were
accepted as authentic synergistic or antagonistic interactions, respectively.
Results: Considering all antimicrobials in combination with tigecycline, chequerboard analysis
showed 5.9% synergy, 85.7% indifference, and 8.3% antagonism. Tigecycline showed synergism with
levofloxacin (4 strains; 16.6%), amikacin (2 strains; 8.3%), imipenem (2 strains; 8.3%) and colistin (2
strains; 8.3%). Antagonism was observed for the tigecycline/piperacillin-tazobactam combination (8
strains; 33.3%). Synergism was detected only among tigecycline non-susceptible strains. Time-kill
assays confirmed the synergistic interaction between tigecycline and levofloxacin, amikacin,
imipenem and colistin for 5 of 7 selected isolates. No antagonism was confirmed by time-kill assays.
Conclusion: This study demonstrates the in vitro synergistic activity of tigecycline in combination
with colistin, levofloxacin, amikacin and imipenem against five tigecycline non-susceptible A.
baumannii strains, opening the way to a more rationale clinical assessment of novel combination
therapies to combat infections caused by MDR and pan-resistant A. baumannii.
Published: 21 May 2009
Annals of Clinical Microbiology and Antimicrobials 2009, 8:18 doi:10.1186/1476-0711-8-18
Received: 24 February 2009
Accepted: 21 May 2009
This article is available from: http://www.ann-clinmicrob.com/content/8/1/18
© 2009 Principe et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Annals of Clinical Microbiology and Antimicrobials 2009, 8:18 http://www.ann-clinmicrob.com/content/8/1/18
Page 2 of 10
(page number not for citation purposes)
Background
Acinetobacter baumannii has emerged as a leading nosoco-
mial pathogen, particularly in Intensive Care Units
(ICUs), where several outbreaks have been described [1].
The epidemic potential and the clinical severity of A. bau-
mannii infections are primarily related to the propensity of
this organism to develop resistance to a variety of antimi-
crobial agents, including broad-spectrum beta-lactams,
aminoglycosides, fluoroquinolones and carbapenems [2].
Carbapenems remain drugs of choice for the treatment of
A. baumannii infection, but their efficacy can be compro-
mised by the spread of novel class D carbapenemases
[3,4]. As a result, carbapenem-intermediate or -resistant A.
baumannii isolates are becoming increasingly prevalent in
several countries [5]. Colistin, an old antibiotic from the
polymixin group, is very effective against multidrug-resist-
ant (MDR) A. baumannii isolates, but the emergence of
resistance has occasionally been experienced [6]. Moreo-
ver, unfavourable pharmacokinetic properties and possi-
ble adverse effects restrict its clinical use [7,8]. Tigecycline,
a new semi-synthetic tetracycline, has provided hope for
the treatment of A. baumannii infections, including car-
bapenem-resistant isolates [9,10]. However, A. baumannii
isolates showing reduced susceptibility to tigecycline have
recently been identified in Israel [11], Spain [12], Italy
[13], USA [14], and China [15]. Moreover, the exposure to
sub-MIC tigecycline concentrations has been shown to
facilitate the development of resistance in A. baumannii
both in vitro and in vivo [16-18]. In this scenario, combi-
nation therapy has become the ultimate resource to treat
MDR and pan-resistant A. baumannii infections [19], but
its actual efficacy is unclear from a microbiological and
clinical viewpoint. Previous investigations revealed an
overall indifferent effect of tigecycline in combination
with other antimicrobial agents commonly used against
Acinetobacter  spp., including carbapenems, fluoroqui-
nolones, rifampicin, ampicillin-sulbactam, piperacillin-
tazobactam, polymyxin B and colistin [20-22]. Only few
clinical studies reported successful in vivo treatment of
MDR A. baumannii infection with tigecycline in combina-
tion with colistin, meropenem, piperacillin-tazobactam
and cotrimoxazole [23,24]. However, these results were
not supported by an in vitro synergy study. Recently, tige-
cycline/amikacin synergistic interactions have been
observed in vitro [22,25], but rarely in case of carbapenem-
resistant A. baumannii strains [25].
The aim of this study was to investigate the in vitro activity
of tigecycline in combination with a variety of commonly
used antimicrobial agents against MDR A. baumannii iso-
lates, including tigecycline intermediate and resistant
strains. Part of this work has been presented at the 48th
ICAAC meeting, Washington DC (USA), 2008 (Poster C1-
3817).
Methods
Bacterial isolates and epidemiological typing
Twenty-two A. baumannii isolates were selected from a
well-characterized set of MDR A. baumannii isolates col-
lected in the period January 2004–June 2005 from the
ICU of 7 general hospitals of the Rome (Italy) urban area
[13,26]. Twenty A. baumannii isolates were obtained from
clinical specimens of ICU patients, and 2 were recovered
from the ICU environment (Table 1). None of the patients
underwent previous treatment with tigecycline. The col-
lection also comprises an index strain (study code 115,
also called ACICU) from an ICU outbreak [27], whose
complete genome has recently been sequenced [28]. The
two prototypic strains for the epidemic European clonal
lineages I (RUH875) and II (RUH134) were included as
reference [29]. The selection criteria for A. baumannii iso-
lates were based on hospital of origin (representing 7 hos-
pitals, named A to G, in the Rome urban area), tigecycline
susceptibility (6 sensitive; 15 intermediate; 3 resistant),
molecular type (RAPD fingerprint, pulsotype and
sequence group as described) [26] and antibiotic resist-
ance profile (Table 1). Since there is no widely accepted
definition for MDR A. baumannii, [30], hereafter we shall
refer to the MDR phenotype as diminished susceptibility
to ≥ 2 of the following drug classes: antipseudomonal
cephalosporins, antipseudomonal carbapenems, β-
lactam-β-lactamase inhibitor combinations, antipseu-
domonal fluoroquinolones and aminoglycosides, accord-
ing to ref. [31]. Twenty-one isolates were genetically
related to either the European clonal lineage I (6 isolates)
or II (15 isolates), and indicated as type 2 or 1, respec-
tively, upon sequence group analysis, RAPD, and pulso-
typing. Typing data have been published elsewhere [26].
In addition, 3 A. baumannii isolates (study codes 50, 75
and 105) showing a variant molecular type were included.
Isolates belonging to RAPD types 1, 1a and 4 were resist-
ant to carbapenems, while those belonging to RAPD types
2 and 2a were susceptible (Table 1).
Antimicrobial agents and MIC assays
Antimicrobial agents were: levofloxacin, piperacillin-tazo-
bactam, amikacin, imipenem, rifampicin, ampicillin-sul-
bactam, colistin, and tigecycline. MIC determinations for
all antibiotics were performed by the broth microdilution
method, according to the Clinical and Laboratory Stand-
ards Institute (CLSI) protocol [32]. All powders were
obtained from the Sigma-Aldrich (Milan, Italy), except
tigecycline (Wyeth-Ayerst, Collegeville, Pennsylvania,
USA). MICs were determined in 96-well microtiter plates
(Costar, Cambridge, Massachusetts, USA) containing
freshly prepared Mueller-Hinton broth (Oxoid, Milan,
Italy), to prevent oxidative degradation of tigecycline in
aqueous solution (Wyeth Research, unpublished data).
The inoculum was adjusted to ~5 × 105 CFU/ml in a 100-
μl final volume, and microtiter plates were visually readAnnals of Clinical Microbiology and Antimicrobials 2009, 8:18 http://www.ann-clinmicrob.com/content/8/1/18
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after incubation for 24 h at 37°C. Escherichia coli ATCC
25922 and Staphylococcus aureus ATCC 29213 were used as
internal quality control strains. The US FDA breakpoints
approved for Enterobacteriaceae  were applied to define
tigecycline susceptibility (susceptibility, ≤ 2 mg/L; resist-
ance, ≥ 8 mg/L). MIC results were interpreted according to
the CLSI breakpoint criteria [32]. The criteria proposed by
Gales et al were used for interpretation of colistin suscep-
tibility [33]. Breakpoints for rifampicin were interpreted
according to Hogg et al [34].
Chequerboard assay
Antibiotic interactions were determined using the cheq-
uerboard assay as previously described [22]. The range of
drug concentration used in the chequerboard analysis was
such that the dilution range encompassed the MIC for
each drug used in the analysis. Broth microdilution plates
were inoculated with each A. baumannii isolate to yield ~5
× 105 CFU/ml in a 100-μl final volume, and incubated for
18 h at 37°C.
Synergy has been defined as requiring a fourfold reduc-
tion in the MIC of both antibiotics in combination, com-
pared with each used alone, measuring the fractional
inhibitory concentration index (FICI). The FICI was calcu-
lated for each combination using the following formula:
FICI = FICA + FICB, where FICA = MIC of drug A in combi-
nation/MIC of drug A alone, and FICB = MIC of drug B in
combination/MIC of drug B alone. The FICI was inter-
preted as follows: synergy, FICI ≤ 0.5; indifference, 0.5 <
FICI ≤ 4; antagonism, FICI > 4 [22].
Time-kill assays
Tubes containing freshly prepared Mueller-Hinton broth
supplemented with the drug were inoculated with A. bau-
mannii isolates to a density of ~5 × 105 CFU/ml in a final
volume of 10 ml and incubated in a shaking bath at 37°C.
Aliquots were removed at time 0, 3, 6, and 24 h post-inoc-
ulation, and serially diluted in saline for determination of
viable counts. Diluted samples (100 μl) were plated on
Mueller Hinton agar plates and bacterial counts were
determined after 18-h incubation at 37°C. The antibiotic
concentrations used in time-kill assays corresponded to
0.5-, 1-, and 2-fold the MIC values in combination as
determined by the chequerboard method, i.e. 2- to 16-
fold lower than the MIC of each antibiotic alone (see
Results). The bactericidal activity was defined as = 3 log10
CFU/ml reduction in the colony count relative to the ini-
tial inoculum [21]. Synergy was interpreted as ≥ 2 log10
decrease in CFU/ml by the drug combination when com-
Table 1: Characteristics of A. baumannii isolatesa
Study code
(Hospital)
Source (isolation date) Sequence group RAPD type Pulsotype Antibiotic resistance profile b
5 (A) Respiratory secretions (06/15/04) 1 1 1 LVX TZP AMK IPM RIF SAM TIG
11 (B) Respiratory secretions (05/15/04) 1 1 1 LVX TZP AMK IPM RIF TIG
16 (B) Respiratory secretions (06/21/04) 1 1 1 LVX TZP AMK IPM TIG
28 (B) Environmental, laryngoscope (06/21/04) 1 1 1 LVX TZP AMK IPM RIF TIG
29 (B) Central venous catheter (07/19/04) 1 1 1 LVX TZP AMK IPM RIF TIG
32 (B) Respiratory secretions (07/13/04) 1 1 1 LVX TZP AMK IPM RIF TIG
50 (C) Respiratory secretions (01/07/04) 4 1a 1 LVX TZP AMK IPM RIF SAM CS
62 (C) Wound swab (03/19/04) 2 2 2 LVX TZP RIF TIG
63 (C) Respiratory secretions (06/21/04) 1 1 1 LVX TZP AMK IPM SAM TIG
71 (C) Environmental, desk surface (07/26/04) 1 1 1 LVX TZP AMK IPM SAM TIG
73 (E) Respiratory secretions (05/28/05) 1 1 1 LVX TZP AMK IPM RIF
75 (C) Wound swab (05/17/05) 2 2a 2 LVX TZP AMK RIF TIG
80 (D) Wound swab (01/24/05) 1 1 1 LVX TZP AMK IPM RIF SAM TIG
82 (D) Wound swab (04/12/04) 2 2 2 LVX TZP RIF TIG
86 (D) Urine (04/11/04) 1 1 1 LVX TZP AMK IPM RIF TIG
87 (D) Central venous catheter (07/06/04) 2 2 2 LVX TZP AMK TIG
88 (D) Respiratory secretions (03/02/04) 2 2 2 LVX TZP RIF TIG
89 (D) Respiratory secretions (02/11/05) 2 2 2 LVX TZP RIF TIG
93 (D) Central venous catheter (10/04/04) 1 1 1 LVX TZP AMK IPM SAM TIG
100 (F) Respiratory secretions (03/01/05) 1 1 1 LVX TZP AMK IPM RIF SAM TIG
105 (C) Cerebrospinal fluid (06/27/05) Variant 4 3 LVX TZP AMK RIF SAM
115 (G) c Blood culture (06/10/05) 1 1 1 LVX TZP AMK IPM RIF SAM
RUH 134d Urine (1982) 2 1 1 SAM
RUH 875d Urine (1984) 1 2 2 SAM RIF
a Data are from refs [13,26].
b Isolates showing an intermediate level of susceptibility were classified as resistant.
c A. baumannii index strain, also called ACICU [27,28].
d Representative of the European clonal lineages I (RUH 875) and II (RUH 134) [29].Annals of Clinical Microbiology and Antimicrobials 2009, 8:18 http://www.ann-clinmicrob.com/content/8/1/18
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pared with its most active constituent, and = 2 log10
decrease in the CFU/ml below the initial inoculum, at any
time point. The drug combination was considered to be
antagonistic for = 2 log10 increase in CFU/ml and indiffer-
ent for < 2 log10 change in CFU/ml [22]. All synergistic
interactions were confirmed by triplicate assays. Only
antibiotic combinations showing synergism or antago-
nism in both chequerboard and time-kill assays were
accepted as authentic synergistic or antagonistic interac-
tions, respectively.
Determination of mutation frequencies for resistance to 
antibiotics
This was performed essentially as described by Miller et al.
[35]. Approximately 108 cells from overnight cultures in
Mueller-Hinton broth were spread onto triplicate Muel-
ler-Hinton agar plates supplemented with the selective
antibiotic at a concentration that was four-fold higher
than the respective MIC for an individual isolate. After 48
h incubation at 37°C, the number of colonies was
counted, and mutation frequencies were expressed as the
mean number of colonies recovered as a fraction of total
viable bacteria plated. Isolates with mutation rates >10-7
were considered to be mutators [36].
Detection of ade genes for active efflux systems
The presence of adeB, adeJ, adeE, and adeY, and of the two-
component regulatory system adeRS which controls Ade-
ABC expression was investigated by PCR as previously
reported [37-39]. The identity of adeB, adeJ, adeR, and adeS
amplicons was confirmed by direct DNA sequencing.
Results
The antibiotic susceptibility levels, expressed as MIC of
levofloxacin, piperacillin-tazobactam, amikacin, imi-
penem, rifampicin, ampicillin-sulbactam, colistin and
tigecycline, were preliminarily determined for the whole
panel of 24 A. baumannii isolates [see Additional file 1].
All isolates, except the prototypic strains for the European
clonal lineages I (RUH 875) and II (RUH 134), were
resistant to levofloxacin and piperacillin-tazobactam (22
isolates each, 91.7%). A high percentage of isolates were
resistant to amikacin (18 isolates, 75.0%), imipenem (15
isolates, 62.5%), and rifampicin (18 isolates, 75.0%),
while only 9 (37.5%) and 1 (4.2%) isolates were resistant
to ampicillin-sulbactam and colistin, respectively. Eight-
een isolates (75.0%) were non-susceptible to tigecycline,
including both resistant and intermediate phenotypes.
Reference strains RUH 875 and RUH 134, isolated in early
1980s, showed an overall susceptible profile (Tables 1
and Additional file 1).
Chequerboard analysis performed with all antimicrobials
in combination with tigecycline showed 5.9% synergy,
85.7% indifference, and 8.3% antagonism (Table 2). Tige-
cycline exerted synergistic activity with levofloxacin (4 iso-
lates), amikacin, imipenem and colistin (2 isolates each).
Notably, synergistic effects were observed only among
tigecycline non-susceptible isolates (Table 2). Antagonis-
tic interactions were frequently observed for tigecycline/
piperacillin-tazobactam (8 isolates), and to a lesser extent
for tigecycline/amikacin (3 isolates), tigecycline/colistin,
tigecycline/ampicillin-sulbactam and tigecycline/
rifampicin (1 isolate each) (Table 2). The concentration of
individual drugs in synergistic combinations is shown in
Table 3.
All synergistic interactions inferred from chequerboard
analysis were reassessed by time-kill kinetic experiments
performed with tigecycline in combination with levo-
floxacin, amikacin, imipenem and colistin. Time-kill dia-
grams for effective combinations are shown in Figure 1.
Five of 10 synergistic combinations, namely tigecycline/
levofloxacin (2 out of 4 isolates), tigecycline/amikacin,
tigecycline/imipenem and tigecycline/colistin (1 out of 2
isolates each) were confirmed. Synergistic effects were
observed at 3 h for tigecycline/colistin (2/0.25 mg/L = 1/
2 MIC for both antibiotics), at 6 h for tigecycline/imi-
penem (0.5/16 mg/L = 1/2 MIC for tigecycline and 1/8
MIC for imipenem) and tigecycline/levofloxacin (0.25/4
mg/L = 1/16 MIC for tigecycline and 1/4 MIC for levo-
floxacin), and at 24 h for tigecycline/amikacin (1/64 mg/
L = 1/4 MIC for both antibiotics). Re-growth was observed
after 24 h for tigecycline/colistin, tigecycline/imipenem
and tigecycline/levofloxacin combinations (Figure 1). No
synergistic combination resulted in bactericidal activity.
Moreover, none of the 14 antagonistic interactions
inferred from chequerboard analysis was confirmed by
time-kill assays (data not shown).
To determine if regrowth in time-kill assays was due to A.
baumannii  hypermutability, the spontaneous mutation
frequency toward antibiotic resistance was determined for
isolates showing regrowth at 24 h (study codes 5, 11, 75,
80) or not (study code 71). Resistant mutants were not
detected (mutation rate <10-8) upon selection with levo-
floxacin, amikacin, imipenem, and colistin at four-fold
the MIC, while tigecycline-resistant mutants generated
with a frequency between 1.2 × 10-8 and 9.0 × 10-8 for all
tested isolates (see Additional file 2).
Search for efflux genes showed that all isolates were posi-
tive for the adeB and adeJ genes and negative for both adeE
and adeY genes, irrespective of their resistance or suscepti-
bility profile. All of the isolates were positive for the two-
component regulatory system adeRS.
Discussion
In this work we investigated tigecycline interactions with
various antimicrobials by a two-step approach, involvingAnnals of Clinical Microbiology and Antimicrobials 2009, 8:18 http://www.ann-clinmicrob.com/content/8/1/18
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preliminary chequerboard screening and subsequent
time-kill assays. The chequerboard is an easy to perform,
high-throughput method which provides single time-
point evidence of bacterial growth inhibition, and gener-
ally results in an overestimate of synergistic interactions
[22]. For these reasons, all effective combinations inferred
from chequerboard analysis were reassessed by time-kill
assays. Although time consuming and cumbersome, the
time-kill assays provide a dynamic picture of antibiotic
action over time [40]. Hence, only combinations showing
synergy in both assays were interpreted as authentic syn-
ergistic interactions.
While chequerboard screening provided synergistic results
for the combinations tigecycline/levofloxacin, tigecycline/
amikacin, tigecycline/imipenem and tigecycline/colistin
in 7 out of 24 isolates, time-kill kinetics confirmed syner-
gism in only 5 out of 7 isolates, 4 of which were resistant
Table 2: Chequerboard results obtained with tigecycline in combination with seven antibiotics in 24 A. baumannii isolates
Effect (FICI value) of TIG in combination with a
Study code LVX TZP AMK IPM RIF SAM CS
5 Sy (0.31) In (2.03) An (4.06) In (0.75) In (0.62) In (1.25) In (0.62)
11 Sy (0.31) In (2.03) Sy (0.50) In (0.75) In (0.62) In (1.50) In (0.56)
16 Sy (0.50) In (1.03) In (0.62) In (0.75) In (1.06) In (1.50) Sy (0.50)
28 In (0.62) In (2.03) An (8.06) In (0.75) In (1.00) In (1.50) In (0.56)
29 In (0.75) In (2.06) In (0.75) In (0.75) In (1.00) In (1.50) In (1.12)
32 In (1.12) In (2.06) In (1.25) In (0.75) In (1.00) In (1.50) In (0.62)
50 In (0.75) An (8.03) In (0.75) In (0.75) In (0.75) In (2.50) In (0.56)b
62 In (1.00) In (1.00) In (1.00) Sy (0.37) In (0.62) In (1.00) In (0.62)
63 In (0.56) In (2.03) In (0.56) In (0.75) In (0.75) In (1.25) In (0.56)
71 In (0.75) In (2.03) Sy (0.50) In (0.75) In (0.56) In (1.25) In (0.56)
73 In (0.75) An (4.06) In (1.12) In (1.12) In (1.50) In (2.50) An (4.25)
75 Sy (0.31) In (0.75) In (0.62) In (0.62) In (0.62) In (0.56) Sy (0.50)
80 In (0.62) An (4.06) In (0.62) Sy (0.37) In (1.00) In (1.25) In (0.62)
82 In (0.56) In (0.75) In (2.12) In (1.25) In (0.62) In (0.75) In (1.25)
86 In (1.00) An (4.06) In (1.00) In (0.75) In (1.00) In (1.50) In (0.56)
87 In (0.56) In (0.75) In (0.56) In (0.75) In (2.12) In (0.75) In (1.12)
88 In (0.62) In (1.00) An (4.03) In (0.75) In (0.75) In (0.62) In (0.75)
89 In (0.62) In (1.50) In (1.06) In (0.75) In (0.75) In (0.75) In (1.12)
93 In (0.56) An (4.06) In (2.06) In (1.00) An (4.25) In (1.00) In (0.62)
100 In (0.56) In (2.03) In (1.00) In (1.00) In (1.00) In (0.75) In (0.62)
105 In (2.03) An (4.03) In (0.75) In (2.50) In (2.50) An (4.25) In (2.25)
115 In (1.06) An (4.06) In (2.25) In (1.50) In (1.50) In (2.25) In (1.06)
RUH 134 In (1.50)c An (4.12) In (0.75) In (1.50)c In (1.00) In (2.12) In (1.06)
RUH 875 In (1.50)c In (2.06) In (2.12) In (1.00)c In (1.00) In (2.06) In (2.12)
a Synergistic and antagonistic interactions are in bold and italics, respectively.
b The FICI value of the tigecycline/colistin combination has been calculated considering a MIC value of 32 mg/L for colistin [see Additional file 1].
c FICI value of tigecycline in combination with levofloxacin and imipenem has been calculated considering a MIC value of 0.125 mg/L for both 
levofloxacin and imipenem [see Additional file 1].
Table 3: MIC values for individual antibiotics alone (as determined by the broth microdilution method) and in effective synergistic 
combination with tigecycline (as determined by the chequerboard method) for seven A. baumannii isolates
MIC (mg/L) a
Study code TIG LVX AMK IPM CS TIG/LVX TIG/AMK TIG/IPM TIG/CS
5 4 16 64 16 0.25 0.25/4 NS NS NS
11 4 16 64 16 0.5 0.25/4 1/16 NS NS
16 8 16 128 16 0.125 2/4 NS NS 2/0.03
62 4 8 2 2 0.25 NS NS 0.25/0.5 NS
71 4 8 256 16 0.5 NS 1/64 NS NS
75 4 16 128 2 0.5 0.25/4 NS NS 1/0.125
80 4 8 128 32 0.25 NS NS 0.25/8 NS
a Breakpoint criteria are provided in Additional file 1.Annals of Clinical Microbiology and Antimicrobials 2009, 8:18 http://www.ann-clinmicrob.com/content/8/1/18
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Time-kill kinetics for confirmed synergistic interactions Figure 1
Time-kill kinetics for confirmed synergistic interactions. (A) TIG/LVX, study code 5; (B) TIG/LVX, study code 11; (C) 
TIG/AMK, study code 71, (D) TIG/IPM, study code 80; (E) TIG/CS, study code 75; (F) Comparison of quantitative change in 
CFU/ml, relative to the most active constituent, for the synergistic interactions. The drug concentrations are as follows: TIG/
LVX, 0.25 and 4 mg/L, respectively (study codes 5 and 11); TIG/AMK, 1 and 64 mg/L, respectively (study code 71); TIG/IPM, 0.5 
and 16 mg/L, respectively (study code 80); TIG/CS, 2 and 0.25 mg/L, respectively (study code 75). The dotted line denotes the 
threshold value to define synergy. Panels show one representative experiment of three replicates.
A B
C D
E F
A B
C D
E FAnnals of Clinical Microbiology and Antimicrobials 2009, 8:18 http://www.ann-clinmicrob.com/content/8/1/18
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to carbapenems and belonged to type 1 (related to the
European clonal lineage II) [26]. The different synergistic
activities observed in A. baumannii isolates sharing the
same epidemiological type [26] probably reflect the varia-
ble expression of different resistance determinants. This
poses the need to test synergistic interactions even in case
of clonal isolates characterized by identical genetic finger-
print and resistance profile.
Three out of five tigecycline synergistic concentrations
observed in this study with time-kill assays exceed the
maximum plasmatic concentration of tigecycline (0.38
mg/L) achievable with a standard dosage [41]. However,
thanks to its pharmacodynamic properties, tigecycline is
rapidly distributed into tissues resulting in up to 78-fold
higher tissue concentrations, compared to plasma
[42,43]. These considerations suggest a clinical usefulness
for some of the synergistic combinations here detected for
tigecycline.
We identified one isolate (study code 71) showing tigecy-
cline/amikacin synergistic interaction at 24 h (1 and 64
mg/L for tigecycline and amikacin, respectively). This
strain was resistant to amikacin (MIC = 256 mg/L) and
showed an intermediate resistance to tigecycline (MIC = 4
mg/L). Although the synergistic concentration for ami-
kacin (64 mg/L) is significantly above the threshold
achievable in clinical treatments with a multi daily dosing
regimen (20–30 mg/L), higher concentrations (65–75
mg/L) can be achieved with a single amikacin daily dose
[44].
In vitro synergistic interactions between tigecycline and
colistin have previously been demonstrated by time-kill
assays in Klebsiella pneumoniae [45] and in vivo for the
treatment of a severe case of MDR Pseudomonas aeruginosa
osteomyelitis [46]. Although several studies have reported
clinical efficacy of colistin [7,8], the synergistic effect of
tigecycline/colistin combination has never been demon-
strated in A. baumannii by time-kill analysis. Here, we
showed for one A. baumannii isolate (study code 75) a
synergistic effect at 3 h of incubation for tigecycline/colis-
tin combination (2 and 0.25 mg/L for tigecycline and col-
istin, respectively), with a subsequent re-growth within 24
h. This strain was susceptible to colistin (MIC = 0.5 mg/L)
and intermediate resistant to tigecycline (MIC = 4 mg/L).
Notably, the colistin synergistic concentration is signifi-
cantly below the serum concentration achievable after
standard dosing regimen (5–6 mg/L) [44,47]. As noted by
various authors [48-50], colistin causes permeabilisation
of the bacterial outer membrane, which would allow
enhanced penetration by and activity of the other antibi-
otic in combination. The tigecycline/colistin synergistic
interaction could therefore have an impact in clinical
practice by reducing the therapeutic dosage of colistin,
and hence the risk of collateral effects which currently rep-
resent a major limitation to its clinical use [7,8].
We also demonstrated a synergistic interaction for the
combination tigecycline/imipenem (0.5 and 16 mg/L for
tigecycline and imipenem, respectively) in one A. bauman-
nii isolate (study code 80), belonging to the epidemic type
1, and carrying the blaOXA-58 gene [26]. It is of note that the
serum concentration achievable during imipenem treat-
ment is 20 mg/L [47]. Thus, the synergistic interaction
tigecycline/imipenem, which has never been described
before for A. baumannii, could represent a valid therapeu-
tic option to combat the increasingly frequent A. bauman-
nii isolates resistant to both these drugs.
Resistance to quinolones is widespread among MDR A.
baumannii strains [51]. In this study, a high percentage of
A. baumannii isolates were resistant to levofloxacin as a
single agent. Here we report for the first time a synergistic
interaction between tigecycline and levofloxacin (0.25
and 4 mg/L respectively) for 2 A. baumannii isolates, at 6
h of incubation. These strains showed full resistance to
levofloxacin (MIC = 16 mg/L) and intermediate resistance
to tigecycline (MIC = 4 mg/L). Also in this instance, the
levofloxacin synergistic concentration is below the maxi-
mum serum concentration (5.9 mg/L) [52].
Even if no undesirable antagonistic combinations were
confirmed in this study by time-kill assay, we detected a
decreased antimicrobial efficacy for the tigecycline/piper-
acillin-tazobactam combination, compared to the antimi-
crobial efficacy of piperacillin-tazobactam alone (data not
shown). This result is worrying considering that tigecy-
cline/piperacillin-tazobactam combination therapy is
often given empirically, without the support of in vitro
interaction assays.
The molecular mechanisms of synergy between tigecy-
cline and the various antibiotics deserve further investiga-
tion. Overexpression of the AdeABC efflux pump has been
demonstrated in tigecycline resistant A. baumannii isolates
[53], and our results indicate that all A. baumannii isolates
tested carry the adeABC/adeIJK genes, suggesting that their
variable expression level – but not their presence per se –
could contribute to the extent of resistance. We also
showed that adeDE  is not present in A. baumannii, in
agreement with previous studies [38,39].
The regrowth after 24 h observed in time-kill experiments
for all confirmed synergistic combination, except for tige-
cycline/amikacin, could reflect the labile nature in solu-
tion of tigecycline due to oxidative degradation (Wyeth
Research, unpublished data) and/or the tendency of A.
baumannii strains to induce resistance on exposure to anti-
microbial agents, especially at sub-MIC concentrations. AtAnnals of Clinical Microbiology and Antimicrobials 2009, 8:18 http://www.ann-clinmicrob.com/content/8/1/18
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present, we are unable to check the tigecycline levels and
therefore we cannot determine if tigecycline was
degraded, at least partially, during the experimental time
course.
Determination of mutation frequencies for resistance to
levofloxacin, amikacin, imipenem, colistin, and tigecy-
cline at four-fold the MIC failed to detect any hypermuta-
tor phenotype for all isolates showing synergy in time-kill
assays, irrespective of regrowth. Moreover, the mutation
frequency toward resistance to tigecycline (~5 × 10-8) or
other antibiotics (<10-8) is incompatible with the
observed regrowth kinetics (Figure 1). Hence, we can only
speculate that regrowth was due to different response of
isolates to antibiotic-induced overexpression of broad-
specificity multidrug efflux systems, like AdeABC and
AdeIJK [16,37-39], rather than hypermutability. Accord-
ing to this hypothesis, the tigecycline/amikacin interac-
tion may have prevented the expression of efflux-based
resistance by a still undefined mechanism, ultimately
resulting in more effective synergism. In fact, a recent
study on tigecycline/amikacin synergistic interactions in
A. baumannii demonstrated the suppression of regrowth at
24 h for this particular antibiotic combination, in full
agreement with our findings [25].
Further studies are needed to elucidate the molecular
mechanisms responsible for synergistic interactions with
tigecycline and to explore their therapeutic potential. It
will also be necessary to combine in vitro findings with
additional pharmacokinetic and pharmacodynamic data
in order to provide more meaningful prediction of the in
vivo efficacy of synergistic combinations in clinical prac-
tice. Lastly, in vitro synergy testing of tigecycline combina-
tions is recommended prior to starting any combined
therapy for treatment of infections sustained by MDR and
pan-resistant A. baumannii.
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